? MilliporeSigma: Top CDMO Performer in 2023 ?? ?? Despite a tough year for biopharma, MilliporeSigma/Merck Group achieved impressive growth in 2023 with revenue reaching $864.8 million. ?? While industry leaders are navigating budget cuts and regulatory changes, there's growing optimism around emerging modalities like gene therapies and antibody-drug conjugates. MilliporeSigma continues to be at the forefront, supporting these advancements with cutting-edge biosafety and characterization testing. ?? Want to know how we can support your development programs with the latest in biosafety testing? ?? Learn more at https://lnkd.in/ecEFiFHn ?? Read more in GEN magazine (September 2024): https://lnkd.in/d7rDzamt #biopharma #biotechnology #pharmaindustry #drugdevelopment #manufacturing #CDMO #MilliporeSigma #BiosafetyTesting
? ?????? ???? ?????????? ???? ???????? ?????????????? ?? ?? 2023 was a challenging year for biopharma companies. However, leading CDMOs* managed to achieve impressive growth, with their combined revenue climbing 7% in 2023: 1?? Lonza ? $7.73 billion 2?? Thermo Fisher Scientific ? $6.967 billion 3?? Catalent Pharma Solutions ? $4.135 billion 4?? Samsung Biologics ? $2.695 billion 5?? WuXi Biologics ? $2.373 billion 6?? Siegfried ? $1.463 billion 7?? Recipharm ? $1.442 billion 8?? FUJIFILM Diosynth Biotechnologies ? $1.376 billion 9?? Boehringer Ingelheim ? $1.191 billion ?? MilliporeSigma/ Merck Group ? $864.8 million ?? While industry leaders are facing uncertainties due to budget cuts and regulatory changes, there’s still optimism for emerging modalities like gene therapies and antibody-drug conjugates! *??????????: ???????????????? ?????????????????????? ?????? ?????????????????????????? ?????????????????????????? ?? Read more ? GEN magazine (September 2024): https://lnkd.in/d7rDzamt Genetic Engineering & Biotechnology News #biopharma #biotechnology #pharmaindustry #drugdevelopment #manufacturing #CDMOs #CRO #CMO
